Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial

BACKGROUND: Doravirine (DOR) is a nonnucleoside reverse-transcriptase inhibitor. In the phase 3 DRIVE-AHEAD trial in treatment-naive adults with human immunodeficiency virus type 1 (HIV-1) infection, DOR demonstrated noninferior efficacy compared with efavirenz (EFV) and superior profiles for neurop...

Descripción completa

Detalles Bibliográficos
Autores principales: Orkin, Chloe, Squires, Kathleen E, Molina, Jean-Michel, Sax, Paul E, Sussmann, Otto, Lin, Gina, Kumar, Sushma, Hanna, George J, Hwang, Carey, Martin, Elizabeth, Teppler, Hedy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246893/
https://www.ncbi.nlm.nih.gov/pubmed/33336698
http://dx.doi.org/10.1093/cid/ciaa822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246893/
https://www.ncbi.nlm.nih.gov/pubmed/33336698
http://dx.doi.org/10.1093/cid/ciaa822

Ejemplares similares